Intra-Cellular Therapies Inc. (ITCI) had a good day on the market for Monday December 09 as shares jumped 13.24% to close at $11.55. About 2.27 million shares traded hands on 14,859 trades for the day, compared with an average daily volume of n/a shares out of a total float of 55.26 million. After opening the trading day at $10.46, shares of Intra-Cellular Therapies Inc. stayed within a range of $11.68 to $10.41.
With today’s gains, Intra-Cellular Therapies Inc. now has a market cap of $638.26 million. Shares of Intra-Cellular Therapies Inc. have been trading within a range of $16.76 and $6.75 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company’s business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Intra-Cellular Therapies Inc. is based out of New York, and has some 73 employees. Its CEO is Sharon Mates.
